- 現金殖利率: 4.81%、總殖利率: 4.81%、5年平均現金配發率: 92.59%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 (10) | 4.53 | 2.95 | 3.50 | 2.94 | 0.00 | 0 | 77.26 | -0.01 | 0.00 | 0 | 77.26 | -0.01 |
| 2022 (9) | 4.40 | 31.74 | 3.40 | 13.33 | 0.00 | 0 | 77.27 | -13.97 | 0.00 | 0 | 77.27 | -13.97 |
| 2021 (8) | 3.34 | -9.97 | 3.00 | -25.0 | 0.00 | 0 | 89.82 | -16.69 | 0.00 | 0 | 89.82 | -16.69 |
| 2020 (7) | 3.71 | 2.77 | 4.00 | 0.0 | 0.00 | 0 | 107.82 | -2.7 | 0.00 | 0 | 107.82 | -2.7 |
| 2019 (6) | 3.61 | -38.5 | 4.00 | -11.11 | 0.00 | 0 | 110.80 | 44.54 | 0.00 | 0 | 110.80 | 44.54 |
| 2018 (5) | 5.87 | 8.7 | 4.50 | 0.0 | 0.00 | 0 | 76.66 | -8.01 | 0.00 | 0 | 76.66 | -8.01 |
| 2017 (4) | 5.40 | 12.73 | 4.50 | 18.42 | 0.00 | 0 | 83.33 | 5.04 | 0.00 | 0 | 83.33 | 5.04 |
| 2016 (3) | 4.79 | -1.44 | 3.80 | 8.57 | 0.00 | 0 | 79.33 | 10.16 | 0.00 | 0 | 79.33 | 10.16 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 24Q3 (20) | 1.50 | 42.86 | -0.66 | 1.31 | 65.82 | -13.25 | 3.68 | 68.81 | -0.81 |
| 24Q2 (19) | 1.05 | -7.08 | -15.32 | 0.79 | -12.22 | -21.78 | 2.18 | 92.92 | -0.91 |
| 24Q1 (18) | 1.13 | 37.8 | 17.71 | 0.90 | -16.67 | 16.88 | 1.13 | -75.11 | 17.71 |
| 23Q4 (17) | 0.82 | -45.7 | -16.33 | 1.08 | -28.48 | 17.39 | 4.54 | 22.37 | 3.18 |
| 23Q3 (16) | 1.51 | 21.77 | 11.03 | 1.51 | 49.5 | 38.53 | 3.71 | 68.64 | 8.48 |
| 23Q2 (15) | 1.24 | 29.17 | 8.77 | 1.01 | 31.17 | 8.6 | 2.20 | 129.17 | 6.8 |
| 23Q1 (14) | 0.96 | -2.04 | 5.49 | 0.77 | -16.3 | 2.67 | 0.96 | -78.18 | 5.49 |
| 22Q4 (13) | 0.98 | -27.94 | -28.99 | 0.92 | -15.6 | -22.69 | 4.40 | 28.65 | 31.34 |
| 22Q3 (12) | 1.36 | 19.3 | 33.33 | 1.09 | 17.2 | 28.24 | 3.42 | 66.02 | 74.49 |
| 22Q2 (11) | 1.14 | 25.27 | 776.92 | 0.93 | 24.0 | 10.71 | 2.06 | 126.37 | 116.84 |
| 22Q1 (10) | 0.91 | -34.06 | 10.98 | 0.75 | -36.97 | 10.29 | 0.91 | -72.84 | 10.98 |
| 21Q4 (9) | 1.38 | 35.29 | 30.19 | 1.19 | 40.0 | 67.61 | 3.35 | 70.92 | -9.95 |
| 21Q3 (8) | 1.02 | 684.62 | 14.61 | 0.85 | 1.19 | 70.0 | 1.96 | 106.32 | -26.32 |
| 21Q2 (7) | 0.13 | -84.15 | -82.67 | 0.84 | 23.53 | 23.53 | 0.95 | 15.85 | -46.33 |
| 21Q1 (6) | 0.82 | -22.64 | -19.61 | 0.68 | -4.23 | -20.93 | 0.82 | -77.96 | -19.61 |
| 20Q4 (5) | 1.06 | 19.1 | 715.38 | 0.71 | 42.0 | -7.79 | 3.72 | 39.85 | 2.76 |
| 20Q3 (4) | 0.89 | 18.67 | 0.0 | 0.50 | -26.47 | 0.0 | 2.66 | 50.28 | 0.0 |
| 20Q2 (3) | 0.75 | -26.47 | 0.0 | 0.68 | -20.93 | 0.0 | 1.77 | 73.53 | 0.0 |
| 20Q1 (2) | 1.02 | 684.62 | 0.0 | 0.86 | 11.69 | 0.0 | 1.02 | -71.82 | 0.0 |
| 19Q4 (1) | 0.13 | 0.0 | 0.0 | 0.77 | 0.0 | 0.0 | 3.62 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/11 | 4.55 | -28.3 | -6.45 | 52.72 | 5.5 | 16.96 | N/A | 0.25 | 5.8 | - |
| 2024/10 | 6.35 | 4.77 | -2.24 | 48.17 | 6.79 | 16.85 | N/A | 0.65 | 5.55 | - |
| 2024/9 | 6.06 | 36.6 | 3.36 | 41.81 | 8.3 | 15.33 | 0.94 | 0.96 | 4.89 | - |
| 2024/8 | 4.44 | -8.22 | 4.72 | 35.75 | 9.18 | 14.01 | 1.03 | 0.41 | 3.94 | - |
| 2024/7 | 4.83 | 2.04 | 14.28 | 31.32 | 9.84 | 14.01 | 1.03 | 0.64 | 3.53 | - |
| 2024/6 | 4.74 | 6.64 | 8.93 | 26.48 | 9.07 | 13.75 | 0.81 | 0.6 | 2.88 | - |
| 2024/5 | 4.44 | -2.73 | -9.25 | 21.75 | 9.1 | 12.99 | 0.86 | 0.53 | 2.28 | - |
| 2024/4 | 4.57 | 14.82 | 35.46 | 17.3 | 15.08 | 11.29 | 0.99 | 0.27 | 1.75 | - |
| 2024/3 | 3.98 | 44.87 | -6.71 | 12.74 | 9.19 | 12.74 | 0.86 | 0.3 | 1.48 | - |
| 2024/2 | 2.75 | -54.34 | -19.22 | 8.76 | 18.36 | 13.59 | 0.8 | 0.2 | 1.18 | - |
| 2024/1 | 6.01 | 24.53 | 50.29 | 6.01 | 50.29 | 15.71 | 0.69 | 0.97 | 0.97 | 因適逢農曆春節連續假期客戶備貨與子公司認列藥證移轉收入所致。 |
| 2023/12 | 4.83 | -0.86 | 12.11 | 54.8 | 8.27 | 16.2 | 0.68 | -0.06 | 5.6 | - |
| 2023/11 | 4.87 | -25.0 | -19.38 | 49.97 | 7.91 | 17.23 | 0.64 | 0.36 | 5.66 | - |
| 2023/10 | 6.5 | 10.78 | 30.47 | 45.1 | 12.01 | 16.59 | 0.66 | 0.51 | 5.31 | - |
| 2023/9 | 5.86 | 38.4 | 10.29 | 38.61 | 9.4 | 14.33 | 0.94 | 1.08 | 5.02 | - |
| 2023/8 | 4.24 | 0.15 | 3.32 | 32.74 | 9.24 | 12.85 | 1.05 | 0.68 | 3.93 | - |
| 2023/7 | 4.23 | -3.44 | 9.96 | 28.51 | 10.18 | 13.51 | 1.0 | 0.49 | 3.25 | - |
| 2023/6 | 4.38 | -10.51 | 16.81 | 24.31 | 10.37 | 12.65 | 0.83 | 0.47 | 2.77 | - |
| 2023/5 | 4.9 | 45.2 | 17.05 | 19.93 | 9.04 | 12.53 | 0.84 | 0.7 | 2.29 | - |
| 2023/4 | 3.37 | -20.92 | -9.44 | 15.03 | 6.67 | 11.03 | 0.95 | 0.41 | 1.59 | - |
| 2023/3 | 4.26 | 25.44 | 16.09 | 11.66 | 12.45 | 11.66 | 0.88 | 0.51 | 1.18 | - |
| 2023/2 | 3.4 | -15.05 | 29.54 | 7.4 | 10.46 | 11.71 | 0.88 | 0.25 | 0.67 | - |
| 2023/1 | 4.0 | -7.1 | -1.81 | 4.0 | -1.81 | 14.35 | 0.72 | 0.42 | 0.42 | - |
| 2022/12 | 4.31 | -28.71 | -8.86 | 50.62 | 11.59 | 15.33 | 0.68 | 0.29 | 5.66 | - |
| 2022/11 | 6.04 | 21.37 | 40.21 | 46.31 | 13.97 | 16.34 | 0.64 | 0.63 | 5.37 | 本月營收包含部份公費流感疫苖銷售及認列「Amphotericin B」微脂體產品權利金收入 |
| 2022/10 | 4.98 | -6.34 | -11.86 | 40.27 | 10.86 | 14.39 | 0.72 | 0.42 | 4.74 | 本月營收包含部分公費流感疫苖銷售 |
| 2022/9 | 5.32 | 29.66 | 36.44 | 35.29 | 15.05 | 13.26 | 0.95 | 0.84 | 4.35 | 本月出貨部分流感疫苖 |
| 2022/8 | 4.1 | 6.58 | 23.59 | 29.97 | 11.93 | 11.69 | 1.08 | 0.53 | 3.51 | - |
| 2022/7 | 3.85 | 2.75 | 13.57 | 25.87 | 10.28 | 11.77 | 1.07 | 0.41 | 2.98 | - |
| 2022/6 | 3.74 | -10.49 | 20.48 | 22.02 | 9.7 | 11.65 | 0.81 | 0.41 | 2.57 | - |
| 2022/5 | 4.18 | 12.32 | 10.41 | 18.28 | 7.72 | 11.58 | 0.82 | 0.52 | 2.16 | - |
| 2022/4 | 3.72 | 1.37 | 5.25 | 14.09 | 6.95 | 10.02 | 0.95 | 0.49 | 1.64 | - |
| 2022/3 | 3.67 | 39.98 | 13.95 | 10.37 | 7.57 | 10.37 | 0.96 | 0.44 | 1.16 | - |
| 2022/2 | 2.62 | -35.62 | 1.34 | 6.7 | 4.37 | 11.43 | 0.87 | 0.25 | 0.72 | - |
| 2022/1 | 4.08 | -13.86 | 6.42 | 4.08 | 6.42 | 13.12 | 0.76 | 0.47 | 0.47 | - |
| 2021/12 | 4.73 | 9.78 | 26.82 | 45.36 | 7.44 | 14.69 | 0.65 | 0.51 | 4.36 | - |
| 2021/11 | 4.31 | -23.7 | 37.61 | 40.63 | 5.56 | 13.85 | 0.69 | 0.45 | 3.85 | 本月營業收入因銷售國內流感疫苗而增加 |
| 2021/10 | 5.65 | 44.99 | 9.34 | 36.32 | 2.72 | 12.86 | 0.74 | 0.74 | 3.4 | 本月及去年同期皆因銷售國內流感疫苗而增加 |
| 2021/9 | 3.9 | 17.45 | -4.65 | 30.67 | 1.59 | 10.6 | 1.19 | 0.59 | 2.67 | - |
| 2021/8 | 3.32 | -2.06 | 9.56 | 26.78 | 2.57 | 9.81 | 1.29 | 0.32 | 2.07 | - |
| 2021/7 | 3.39 | 9.08 | 8.15 | 23.46 | 1.65 | 10.28 | 1.23 | 0.36 | 1.76 | - |
| 2021/6 | 3.1 | -18.03 | 11.66 | 20.07 | 0.62 | 10.43 | 1.02 | 0.43 | 1.4 | - |
| 2021/5 | 3.79 | 7.08 | 41.83 | 16.97 | -1.16 | 10.55 | 1.01 | -0.4 | 0.98 | - |
| 2021/4 | 3.54 | 9.6 | -0.64 | 13.18 | -9.08 | 9.35 | 1.14 | 0.36 | 1.38 | - |
| 2021/3 | 3.23 | 24.66 | -20.84 | 9.64 | -11.83 | 9.64 | 1.08 | 0.36 | 1.02 | - |
| 2021/2 | 2.59 | -32.39 | -16.4 | 6.42 | -5.58 | 10.15 | 1.03 | 0.18 | 0.66 | - |
| 2021/1 | 3.83 | 2.53 | 3.46 | 3.83 | 3.46 | 10.7 | 0.98 | 0.48 | 0.48 | - |
| 2020/12 | 3.73 | 19.22 | 1.63 | 42.22 | -5.46 | 12.03 | 0.92 | 0.3 | 4.49 | - |
| 2020/11 | 3.13 | -39.36 | -16.51 | 38.49 | -6.34 | 12.38 | 0.9 | 0.2 | 4.19 | - |
| 2020/10 | 5.17 | 26.43 | 38.59 | 35.36 | -5.32 | 12.28 | 0.9 | 0.48 | 3.99 | 月營收增加主因為國內流感疫苗銷售增加所致 |
| 2020/9 | 4.09 | 34.97 | 3.92 | 30.19 | -10.19 | 10.24 | 1.16 | 0.75 | 3.5 | - |
| 2020/8 | 3.03 | -3.32 | -23.53 | 26.1 | -12.05 | 8.86 | 1.34 | 0.21 | 2.75 | - |
| 2020/7 | 3.13 | 15.69 | -13.2 | 23.08 | -10.29 | 8.51 | 1.4 | 0.32 | 2.54 | - |
| 2020/6 | 2.71 | 1.34 | -25.74 | 19.87 | -10.15 | 8.94 | 1.2 | 0.21 | 2.19 | - |
| 2020/5 | 2.67 | -24.98 | -27.78 | 17.17 | -7.07 | 10.36 | 1.03 | 0.28 | 1.98 | - |
| 2020/4 | 3.56 | -13.74 | -0.68 | 14.49 | -1.89 | 10.84 | 0.99 | 0.4 | 1.7 | - |
| 2020/3 | 4.13 | 30.74 | 20.88 | 10.98 | -1.83 | 10.98 | 0.75 | 0.55 | 1.32 | - |
| 2020/2 | 3.16 | -14.7 | 11.16 | 6.86 | -11.8 | 10.53 | 0.79 | 0.27 | 0.77 | - |
| 2020/1 | 3.7 | 0.72 | -25.02 | 3.7 | -25.02 | 0.0 | N/A | 0.5 | 0.5 | - |
| 2019/12 | 3.67 | -2.06 | -2.5 | 44.77 | 10.91 | 0.0 | N/A | 0.13 | 5.54 | - |
